Ryan Lake - Recro Pharma President
President
Mr. Ryan D. Lake is Chief Financial Officer of the Company. Mr. Lake joined Recro in June 2017 as the Company Chief Accounting Officer, and he has over 15 years of senior financial leadership experience. Prior to joining Recro, Mr. Lake served as Chief Financial Officer and Vice President of Finance of Aspire Bariatrics, Inc., a privatelyheld, commercialstage, medical device company. From 2012 to 2015, Mr. Lake held executive management and senior finance positions, including Director of the Natural Materials Division, Controller and Senior Director of Finance, at DSM Biomedical, a division of Royal DSM, a global sciencebased company active in health, nutrition and materials. From 2002 to 2012, Mr. Lake held various senior financial positions of increasing responsibility, most notably Senior Director of Finance and Interim CFO, with Kensey Nash Corporationrationration, a Nasdaqlisted, medical device company. Earlier in his career, Mr. Lake worked at Deloitte Touche, LLP since 2018.
| Age | 39 |
| Tenure | 6 years |
| Phone | 770-534-8239 |
| Web | https://www.recrogainesville.com |
Recro Pharma Management Efficiency
The company has return on total asset (ROA) of (3.72) % which means that it has lost $3.72 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (140.93) %, meaning that it created substantial loss on money invested by shareholders. Recro Pharma's management efficiency ratios could be used to measure how well Recro Pharma manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 102.32 M in liabilities with Debt to Equity (D/E) ratio of 2.3, implying the company greatly relies on financing operations through barrowing. Recro Pharma has a current ratio of 4.27, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Recro Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Recro Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Recro Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Recro to invest in growth at high rates of return. When we think about Recro Pharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jose Duran | Volaris | 56 | |
| Jaime Fernandez | Volaris | 55 | |
| Tracy Tulle | Allegiant Travel | N/A | |
| Ponder Harrison | Allegiant Travel | 54 | |
| Andrew Levy | United Airlines Holdings | 46 | |
| Sonia Burdeus | Volaris | 49 | |
| Ted Bogich | Boyd Gaming | N/A | |
| Carolyn Prowse | Volaris | 46 | |
| Andrew Nocella | United Airlines Holdings | 54 | |
| Theodore Bogich | Boyd Gaming | 68 | |
| Richard Corrado | Air Transport Services | 64 | |
| Christopher Eng | Summit Hotel Properties | 53 | |
| Paul Ruiz | Summit Hotel Properties | 58 | |
| Irene Foxhall | United Airlines Holdings | 62 | |
| Chris Kenny | United Airlines Holdings | 53 | |
| Stephen Thompson | Boyd Gaming | 64 | |
| William Conkling | Summit Hotel Properties | 48 | |
| Holger Blankenstein | Volaris | 49 | |
| James OGrady | Air Transport Services | N/A | |
| Craig Aniszewski | Summit Hotel Properties | 57 | |
| Jonathan Stanner | Summit Hotel Properties | 43 | |
Management Performance
| Return On Equity | -140.93 | |||
| Return On Asset | -3.72 |
Recro Pharma Leadership Team
Elected by the shareholders, the Recro Pharma's board of directors comprises two types of representatives: Recro Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Recro. The board's role is to monitor Recro Pharma's management team and ensure that shareholders' interests are well served. Recro Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Recro Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stewart McCallum, Chief Medical Officer | ||
| Karen Flynn, Independent Director | ||
| Susan Kim, IR Contact Officer | ||
| Alfred Altomari, Independent Director | ||
| Winston Churchill, Independent Director | ||
| Bryan Reasons, Independent Director | ||
| Arnaud Ajdler, Independent Director | ||
| Ryan Lake, Senior Vice President - Finance, Chief Accounting Officer | ||
| Fred Graff, Chief Commercial Officer | ||
| Geraldine Henwood, CEO and President and Director | ||
| Michael Celano, CFO | ||
| Michael Berelowitz, Independent Director | ||
| Wayne Weisman, Independent Chairman of the Board | ||
| William Ashton, Independent Director | ||
| Abraham Ludomirski, Independent Director | ||
| Diane Myers, Sr. VP of Regulatory and Quality Assurance | ||
| Gerri Henwood, President CEO, Director | ||
| Jyrki Mattila, Executive Vice President - Business Development | ||
| Donna Nichols, Principal Financial Officer, Chief Accounting Officer, VP and Corporate Controller | ||
| Randall Mack, Sr. VP of Devel. and Secretary |
Recro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Recro Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -140.93 | |||
| Return On Asset | -3.72 | |||
| Profit Margin | (32.85) % | |||
| Operating Margin | (12.58) % | |||
| Current Valuation | 161.34 M | |||
| Shares Outstanding | 46.61 M | |||
| Shares Owned By Insiders | 1.64 % | |||
| Shares Owned By Institutions | 64.62 % | |||
| Number Of Shares Shorted | 820.81 K | |||
| Price To Earning | (4.08) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Recro Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Recro Pharma's short interest history, or implied volatility extrapolated from Recro Pharma options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Recro Stock
If you are still planning to invest in Recro Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Recro Pharma's history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |